BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1297644)

  • 21. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptorelin (D-Trp-6-LHRH) in combination with carboplatin-containing polychemotherapy for advanced ovarian cancer: a pilot study.
    Medl M; Peters-Engel C; Fuchs G; Leodolter S
    Anticancer Res; 1993; 13(6B):2373-6. PubMed ID: 8135470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study.
    Peters-Engl C; Medl M; Denison U; Sevelda P; Leodolter S; Petru E
    Anticancer Res; 2001; 21(5):3701-6. PubMed ID: 11848547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy for advanced ovarian cancer.
    Schwartz PE; Chambers JT; Makuch R
    Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
    Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO
    Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
    Coleman RL; Bagnell KG; Townley PM
    Cancer J Sci Am; 1997; 3(4):246-53. PubMed ID: 9263631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
    Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
    Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.
    Malmström H; Simonsen E; Westberg R
    Gynecol Oncol; 1994 Jan; 52(1):20-5. PubMed ID: 8307496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
    Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
    Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy in radically operated advanced ovarian cancer.
    Petru E; Pickel H; Lahousen M; Boike G; Heydarfadai M
    Cancer Treat Rev; 1990 Sep; 17(2-3):329-34. PubMed ID: 2272048
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparison of preoperative and postoperative chemotherapy in the treatment of advanced ovarian cancer].
    Hirabayashi K; Okada E; Nakazuma Y; Akamatsu Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jun; 41(6):647-52. PubMed ID: 2671201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.